The aim of this study was to evaluate the use of cyclosporin enemas in patients with distal ulcerative colitis and 'pouchitis' resistant to all conventional medical therapy. In an trial 12 patients with distal ulcerative colitis unresponsive to treatment with topical and oral corticosteroids, 5-aminosalicylic acid, and oral immunosuppressive therapy together with 1 patient with 'pouchitis' unresponsive to repeated courses of antibiotics, topical corticosteroids, and oral mesalazine received 250 mg cyclosporin administered daily as a retention enema. Changes in symptoms and the sigmoidoscopic/histologic appearances of the rectal mucosa were assessed at monthly intervals. Seven of 12 patients with ulcerative colitis improved. There was a strong correlation between clinical and histologic improvement (p < 0.005). Four of 12 patients showed no response. Three of these required colectomy, two of whom had more extensive disease than had previously been documented. The patient with pouchitis showed improvement in symptoms and 'pouchoscopy' appearance but not in histologic score. Cyclosporin blood concentrations were very low and side effects negligible. Cyclosporin A retention enemas are safe and may be useful in the treatment of severe refractory distal ulcerative colitis. A controlled trial would now seem warranted.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/00365529309098276 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Impact of Advanced Medical Therapies on Time to Resection and Colorectal Cancer Outcomes in Ulcerative Colitis Patients Undergoing Colectomy.
J Crohns Colitis
January 2025
Department of Surgery, Amsterdam University Medical Centre, location VUMC, Amsterdam, The Netherlands.
Background: We aimed to evaluate the impact of advanced medical therapies (biologicals and small molecules) on time to colectomy and oncological outcomes in UC.
Methods: This cohort study included UC patients who underwent colectomy between 2003 and 2022 at two referral centres in Belgium and the Netherlands. Exposure was use of advanced medical therapies.
Fluorescent Properties of Mesalazine-Loaded Hydrogel Nanocomposites for the Treatment of Ulcerative Colitis.
J Fluoresc
January 2025
Infectious Disease Department, Hangzhou First People's Hospital Tonglu Hospital, Hangzhou, Zhejiang, China.
This study synthesizes a novel three-dimensional (3D) porous coordination polymer (CP), {[Co(L)₀.₅(H₂O)]·NMP·H₂O} (1), via a solvothermal method in a mixed solvent of water and NMP (1-methyl-2-pyrrolidinone), reacting Co(II) ions with H₄L (1,4-bis(5,6-carboxybenzimidazolylmethyl)benzene). The CP exhibits unique fluorescence properties, emitting at 420 nm under UV light excitation at 350 nm, and serves as a carrier for Mesalazine (MSZ) in therapeutic applications.
View Article and Find Full Text PDFDiagnosis and management of inflammatory bowel disease after solid organ transplantation in the era of biologic therapy: a case series.
Front Transplant
January 2025
Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, MN, United States.
Introduction: The clinical characteristics of inflammatory bowel disease (dnIBD) diagnosed after solid organ transplant (SOT) are not well-described, particularly since the advent of biologic therapy for treatment of IBD.
Methods: We conducted a single-center, retrospective review of SOT recipients between 2010 and 2022 at the University of Minnesota Medical Center who were diagnosed with IBD after transplant.
Results: Of 89 patients at our center with IBD and a history of SOT, five (5.
Photodynamic therapy with a novel photosensitizer inhibits DSS-induced ulcerative colitis in rats via the NF-κB signaling pathway.
Front Pharmacol
January 2025
Tianjin Key Laboratory of Biomedical Material, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Introduction: Ulcerative colitis (UC) is an inflammatory bowel disease characterized by inflammation and ulceration of the digestive tract.
Methods: Photodynamic therapy (PDT) with a novel photosensitizer LD was used to treat UC rat models to explore the therapeutic effect and mechanism of LD-PDT on UC. 16S ribosomal RNA was used to detect the composition of Gut microbiota.
Huanglian Ejiao Decoction Alleviates Ulcerative Colitis in Mice Through Regulating the Gut Microbiota and Inhibiting the Ratio of Th1 and Th2 Cells.
Drug Des Devel Ther
January 2025
The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, 310053, People's Republic of China.
Background: Huanglian-ejiao decoction (HED) is a Chinese traditional medicinal formula evolved from the Shanghan Lun (Treatise on Febrile Diseases). However, HED ultimate mechanism of action remained indistinct. Therefore, this study aimed to investigate whether HED could exert anti-inflammatory effects on 2,4,6-Trinitrobenzenesulfonic acid (TNBS)-induced colitis (UC) model through the regulation of CD4T subsets and gut microbiota.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!